Close

Guggenheim Starts Theravance Biopharma (TBPH) at Buy

June 20, 2016 6:16 AM EDT Send to a Friend
Guggenheim initiates coverage on Theravance Biopharma (NASDAQ: TBPH) with a Buy rating and a price target of $30.00.Analyst Louise Chen ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login